Publication|Articles|November 16, 2026

Psychiatric Times

  • Vol 43, Issue 11

The Change That Counts: Rethinking Reproductive Depression Across the Lifespan

Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.

Women experience twice the rate of lifetime major depressive disorder compared with men, an increased risk that is limited to their reproductive years (menarche through menopause). Vulnerability to depressive symptoms and major depressive episodes in women corresponds with periods of hormonal fluctuation, including the menstrual cycle (specifically the premenstrual period), pregnancy and postpartum, and perimenopause. Approximately 5.5% of cycling women experience premenstrual dysphoric disorder (PMDD), a debilitating disorder in which women experience severe mood changes, anxiety, and irritability in the week or two before menses onset.1,2 Perinatal depression affects more than 20% of mothers globally, including depressive episodes during pregnancy and the postpartum period.3 Observed rates of perimenopausal depression are between 20% and 40% across studies, with rates as high as 59% in women with a prior history of major depressive disorder.4

Although these disorders are identified and treated as 3 separate conditions, a converging body of evidence suggests shared mechanisms between these hormone-sensitive or reproductive mood disorders.5 In PMDD, perinatal depression, and perimenopausal depression, it is the change in reproductive hormones—and how the brain responds to this change—that triggers symptom onset, and a history of any one of these disorders increases risk for the others.

Studying Hormone-Sensitive Mood Disorders in Women

A central nervous system (CNS) biological sensitivity to fluctuating hormones in women with these disorders has been demonstrated through several well-controlled, experimental studies. These studies share a common design: Suppress ovarian hormone production with a gonadotropin-releasing hormone (GnRH) agonist (typically leuprolide), and then add back and subsequently withdraw estradiol and/or progesterone.6-11

What follows is a review of these studies by reproductive mood disorder.

PMDD

Schmidt and colleagues (1998) utilized this paradigm in women with and without PMDD.6 After ovarian suppression, add-back of either estradiol or progesterone triggered negative mood symptoms in women with PMDD, whereas women without PMDD showed mood stability during addback.6 Importantly, these findings were recently replicated in a much larger clinical sample.7 A follow-up study in 2017 clarified what triggers this response by administering estradiol and progesterone for several months.8 Women with PMDD displayed negative mood symptoms at initial add-back, but these symptoms resolved once the hormone levels were stable, even though the levels remained elevated.8 This finding clearly demonstrates that it is the change or fluctuation in hormones, not the level of hormones themselves hitting a critical threshold, that precipitates mood symptoms. Clinically, this explains why continuous ovarian suppression (via GnRH agonists such as leuprolide or continuous combined oral contraceptives) can be an effective treatment for PMDD.

Perinatal Depression

In 2000, Bloch and colleagues applied this paradigm in a study of simulated pregnancy and parturition. Women with and without histories of postpartum depression (PPD) underwent ovarian suppression, followed by 8 weeks of supraphysiologic estradiol and progesterone add-back (simulating pregnancy-level hormones) and withdrawal (simulating postpartum withdrawal). Negative mood symptoms were only triggered in women with a history of PPD. Symptoms were significantly elevated following withdrawal but were also elevated during add-back. Women who had a history of pregnancy but not of PPD did not develop symptoms, suggesting that PPD is triggered by peripartum hormone change in biologically susceptible women.9

A 2024 replication of this study showed that hormone-sensitive women with a history of PPD develop negative mood symptoms during experimental hormone change, whereas those without a history of PPD who are not hormone sensitive did not. Of note, symptoms of anger and irritability were triggered by add-back, but symptoms of feeling depressed or blue and rejection sensitivity were highest during withdrawal, indicating a differential sensitivity to rising hormones (similar to early pregnancy changes) compared with falling hormones (similar to changes after delivery).10

Perimenopausal Depression

This experimental paradigm has also been applied to the perimenopausal transition. Schmidt and colleagues (2015) used transdermal estrogen patches to stabilize estradiol levels in women with a history of perimenopausal depression who were euthymic after receiving hormone replacement therapy and in women with no history of major depressive disorder and no perimenopausal depression. After 3 weeks on the patch, women were randomly assigned to continued estradiol or placebo (which induced a withdrawal from estradiol). Withdrawal triggered depressive symptoms only in women with a history of perimenopausal depression; women without a history did not show depressive symptoms. Women with a history of perimenopausal depression who continued estradiol therapy remained asymptomatic, once again demonstrating the importance of hormone fluctuation, but not absolute levels, in inducing symptoms in susceptible women.11

The Biology of Hormone-Sensitive Mood Disorders

Across the experimental studies of these 3 vulnerable reproductive transitions, a common theme emerges: Mood symptoms coincide with large changes, either increases or decreases, in ovarian hormones.6-11 This commonality groups these disorders under an umbrella of reproductive and hormone-sensitive depression, likely rooted in a CNS sensitivity to fluctuating hormones in some women. One hypothesized mechanism of this sensitivity involves the coordinated effects of progesterone-derived neuroactive steroids, such as allopregnanolone, on γ-aminobutyric acid (GABA)–ergic signaling in the brain. Allopregnanolone is a positive allosteric modulator at the GABAA receptor—it enhances inhibitory GABAergic signaling, typically inducing a calm, nonanxious state. Neuroactive steroids such as allopregnanolone have been implicated in the development of (and treatment for) each of the hormone-sensitive mood disorders discussed: PMDD,12,13 perinatal depression,14,15 and perimenopausal depression.16,17 Sensitivity of the GABAA receptor to allopregnanolone and other neuroactive steroids is determined by its subunit composition, which is highly plastic and also influenced by circulating levels of neuroactive steroids. Therefore, coordination between GABAA receptor subunit composition and neuroactive steroid levels is key in maintaining optimal GABAergic signaling. Disruption of this coordinated interaction could lead to aberrant signaling and subsequent negative mood symptoms, as suggested by preclinical models of PPD.18

For example, maladaptive subunit expression in the context of large fluctuations in steroid hormones and their neuroactive steroid metabolites may lead to deficient sensitivity and binding affinity of the GABAA receptor to allopregnanolone, diminishing its anxiolytic effects. Disturbances along the metabolic pathway that synthesizes neuroactive steroids from progesterone may result in the synthesis of more negative GABAA receptor modulators than positive, anxiolytic modulators such as allopregnanolone, leading to less inhibitory signaling.19 Research on this mechanism of action is ongoing, and treatments such as zuranolone (Zurzuvae), an oral synthetic analog of allopregnanolone that is FDA approved to treat PPD, show promise for targeting this pathway in the treatment of depression.15,20

Concluding Thoughts

Conceptualizing and assessing reproductive depression across the lifespan is clinically important. A history of PMDD should alert clinicians to an increased risk of PPD, and a history of either PMDD or PPD should prompt awareness of an increased risk of perimenopausal depression. Clinicians should anticipate the possibility of mood destabilization during times of reproductive hormone change and work with patients to develop a plan for monitoring and managing symptoms. When hormone therapy is indicated for patients who are at risk or currently experiencing symptoms, continuous or stabilization-based approaches (such as continuous birth control pills) may reduce risk or worsening of symptoms.

Perhaps more importantly, ongoing research into the pathophysiology of reproductive mood disorders may provide broader insights into how psychiatric disorders arise. Reproductive mood disorders share a common biological trigger—reproductive hormonal change—that can lead to clinically significant mood symptoms in vulnerable individuals. Understanding how hormonal fluctuations affect the CNS and initiate the cascade of biological changes that ultimately produce mood symptoms may shed light on the development of mood disorders more broadly and, ultimately, lead to more personalized and targeted treatments. Thus, research on reproductive mood disorders has the potential to usher in a new era of psychiatry—one in which the biological vulnerabilities underlying psychiatric illness are identified and understood, making the prevention of psychiatric illness a realistic possibility.

Dr Payne is vice chair of research, professor of psychiatry and neurobehavioral sciences, and director of the Reproductive Psychiatry Research Program at the University of Virginia in Charlottesville.

Dr Wenzel is a postdoctoral fellow at the University of Virginia.

References

1. Reilly TJ, Patel S, Unachukwu IC, et al. The prevalence of premenstrual dysphoric disorder: systematic review and meta-analysis. J Affect Disord. 2024;349:534-540.

2. Peters JR, Schmalenberger KM, Eng AG, Stumper A, Martel MM, Eisenlohr-Moul TA. Dimensional Affective Sensitivity to Hormones across the Menstrual Cycle (DASH-MC): a transdiagnostic framework for ovarian steroid influences on psychopathology. Mol Psychiatry. 2025;30(1):251-262.

3. Al-Abri K, Edge D, Armitage CJ. Prevalence and correlates of perinatal depression. Soc Psychiatry Psychiatr Epidemiol. 2023;58(11):1581-1590.

4. Bromberger JT, Schott L, Kravitz HM, Joffe H. Risk factors for major depression during midlife among a community sample of women with and without prior major depression: are they the same or different? Psychol Med. 2015;45(8):1653-1664.

5. Payne JL, Palmer JT, Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harv Rev Psychiatry. 2009;17(2):72-86.

6. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209-216.

7. Wei SM, Wakim P, Martinez PE, Nieman LK, Rubinow DR, Schmidt PJ. Differential effects of ovarian steroids in women with and without premenstrual dysphoric disorder: a replication and extension of findings. Am J Psychiatry. 2025;182(10):922-934.

8. Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174(10):980-989.

9. Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry. 2000;157(6):924-930.

10. Eisenlohr-Moul T, Swales DA, Rubinow DR, Schiff L, Schiller CE. Temporal dynamics of neurobehavioral hormone sensitivity in a scaled-down experimental model of early pregnancy and parturition. Neuropsychopharmacology. 2024;49(2):414-421.

11. Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015;72(7):714-726.

12. Bäckström T, Ekberg K, Hirschberg AL, et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021;133:105426.

13. Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress. 2020;12:100213.

14. Meltzer-Brody S, Kanes SJ. Allopregnanolone in postpartum depression: role in pathophysiology and treatment. Neurobiol Stress. 2020;12:100212.

15. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180(9):668-675.

16. Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T. Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl). 2006;187(2):209-221.

17. Joffe H, de Wit A, Coborn J, et al. Impact of estradiol variability and progesterone on mood in perimenopausal women with depressive symptoms. J Clin Endocrinol Metab. 2020;105(3):e642-e650.

18. Maguire J, Mody I. GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008;59(2):207-213.

19. Osborne LM, Etyemez S, Pinna G, et al. Neuroactive steroid biosynthesis during pregnancy predicts future postpartum depression: a role for the 3α and/or 3β-HSD neurosteroidogenic enzymes? Neuropsychopharmacology. 2025;50(6):904-912.

20. Clayton AH, Suthoff E, Jain R, et al. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: an integrated analysis of 4 randomized clinical trials. J Affect Disord. 2024;351:904-914.


Related to this article